NorthWest Biotherapeutics Inc (NWBO)

[slappdaddy]

Prognosis is usually reported in years of "median survival." Median survival is the time at which an equal number of patients do better and an equal number of patients do worse. With standard treatment, median survival for adults with an anaplastic astrocytoma is about two to three years. For adults with more aggressive glioblastoma, treated with concurrent temozolamide and radiation therapy, median survival is about 14.6 months and two-year survival is 30%.

You were saying? It looks like DCVAX-L P3 survivors are nothing special compared to other treatments. U clowns are crazy supporting this penny stock!